BeOne Medicines Ltd.
ONC
Positions held
Your positionsONC isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- BeOne Medicines Ltd. operates in a competitive biotechnology sector with a strong focus on innovative therapies, positioning itself well against traditional pharmaceutical companies.
- Revenue increased by 13% compared to the prior quarter, reaching $1.7 billion.
- Operating margin expanded to 19.1%, up from 16.5% in the previous quarter.
- Despite recent growth, BeOne Medicines has faced significant operating losses in previous years, indicating potential volatility.
- The company reported a net income loss of $881.7 million in 2023, reflecting ongoing financial challenges.
- The stock has a trailing P/E ratio of 64.9, suggesting it may be overvalued compared to its earnings growth potential.
Fundamentals
| Market cap | $39.83B | Enterprise value | $36.76B | Trailing P/E | 62.64 | Forward P/E | 34.15 |
| PEG | 0.77 | Price / book | 7.65 | Beta | 0.61 | Dividend yield | 0.00% |
| Revenue growth | 29.6% | Earnings growth | 166.7% | Gross margin | 88.9% | Operating margin | 19.1% |
| Profit margin | 10.7% | ROE | 14.7% | ROA | 7.5% | Debt / equity | 0.40 |
| Current ratio | 3.41 | Free cash flow | $879.02M | Analyst recommendation | strong_buy | Mean target | $435.53 |
| 52w high | $385.22 | 52w low | $253.95 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.7B | $1.5B | $1.5B | $1.4B | $1.3B | — |
| Op margin | 19.1% | 16.5% | 12.4% | 11.5% | 6.7% | — |
| Net income | $237M | $227M | $66.5M | $125M | $94.3M | — |
| Gross margin | 89.8% | 89.0% | 90.5% | 86.1% | 87.5% | — |
| Gross profit | $1.5B | $1.3B | $1.4B | $1.2B | $1.2B | — |
| Operating income | $325M | $250M | $185M | $163M | $87.9M | — |
- Revenue +13% vs prior quarter ($1.7B vs $1.5B).
- Gross margin 89.8% (was 89% prior quarter).
- Operating margin expanded to 19.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $5.3B | $3.8B | $2.5B | $1.4B | — |
| Op margin | 8.4% | -14.9% | -49.1% | -126.4% | — |
| Net income | $287M | -$645M | -$882M | -$2.0B | — |
| Gross margin | 87.5% | 84.4% | 84.5% | 79.8% | — |
| Gross profit | $4.7B | $3.2B | $2.1B | $1.1B | — |
| Operating income | $447M | -$568M | -$1.2B | -$1.8B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-01 · Biotech Leader BeOne Medicines Poised To Hit Early Buy Points
2026-09-05 · BeOne Medicines (ONC) Stock May Be Fully Priced After An 86% Run
2026-09-05 · The Bull Case For BeOne Medicines (ONC) Could Change Following US-Backed HER2 Regimen And Onshoring Deal
2026-09-01 · FDA Approval Marks A Turning Point For BeOne Medicines (ONC)
2026-09-01 · Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
2026-09-01 · BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
2026-08-31 · BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
2026-08-27 · Generative "AI" Macro Data Shows U.S. Impacts
2026-08-27 · BeOne Medicines Ltd. - Sponsored ADR (ONC) is a Great Momentum Stock: Should You Buy?
2026-08-25 · BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA
Price (daily)
Full chart · RSI · MACD · patterns